Document Detail

Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide.
MedLine Citation:
PMID:  19191785     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE To evaluate the effects of combined treatment with docetaxel and octreotide, a somatostatin analogue, on human hormone- and drug-refractory prostate cancer cell lines, PC-3 and DU-145, and on some growth factors related to tumour growth and angiogenesis in prostate cancer. MATERIALS AND METHODS A cell proliferation assay was used to assess the cytotoxicity of the drugs. To verify apoptosis, both DNA fragmentation (by enzyme-linked immunosorbent assay) and caspase 3/7 activity were measured. We also investigated the effect of combined docetaxel and octreotide on growth factors secreted from prostate cancer cells using a human growth factor antibody array. RESULTS The combination of docetaxel and octreotide resulted in significant synergistic cytotoxic activity and apoptosis, which was dose- and time-dependent. The combined treatment also resulted in significantly less secretion of stem cell factor and platelet-derived growth factor-AB in PC-3 cells, and transforming growth factor-beta and basic fibroblast growth factor in DU-145 cells, than in untreated controls. CONCLUSION Octreotide, a somatostatin analogue, combined with docetaxel might provide a rationale treatment option for hormone-refractory prostate cancer cells, not only by direct inhibition of cell proliferation but also by inhibiting the secretion of growth factors.
Cigdem Erten; Burcak Karaca; Yuksel Kucukzeybek; Gurbuz Gorumlu; Ercument Cengiz; Mustafa K Gul; Harika Atmaca; Selim Uzunoglu; Bulent Karabulut; Ulus A Sanli; Ruchan Uslu
Related Documents :
18959755 - Altered expression of tumor protein d52 regulates apoptosis and migration of prostate c...
12210485 - Enhanced expression of vimentin in motile prostate cell lines and in poorly differentia...
11241555 - Long-term exposure of tumor necrosis factor alpha causes hypersensitivity to androgen a...
21028825 - Preparation and evaluation of carborane analogues of tamoxifen.
2835865 - Expression of the spleen focus-forming virus envelope gene in a polarized epithelial ce...
6272545 - Effect of pituitary intermediate lobe extract on steroid production by the isolated zon...
Publication Detail:
Type:  Journal Article     Date:  2009-02-03
Journal Detail:
Title:  BJU international     Volume:  104     ISSN:  1464-410X     ISO Abbreviation:  BJU Int.     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-08-03     Completed Date:  2009-09-02     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  100886721     Medline TA:  BJU Int     Country:  England    
Other Details:
Languages:  eng     Pagination:  107-14     Citation Subset:  IM    
Division of Medical Oncology, Tulay Aktas Oncology Hospital, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cell Line, Tumor
Drug Resistance, Neoplasm / drug effects*
Drug Synergism
Enzyme-Linked Immunosorbent Assay
Intercellular Signaling Peptides and Proteins / metabolism*
Neoplasms, Hormone-Dependent / drug therapy*,  metabolism,  pathology
Octreotide / administration & dosage
Prostate / metabolism*,  pathology
Prostatic Neoplasms / drug therapy*,  metabolism,  pathology
Taxoids / administration & dosage
Treatment Outcome
Reg. No./Substance:
0/Intercellular Signaling Peptides and Proteins; 0/Taxoids; 15H5577CQD/docetaxel; 83150-76-9/Octreotide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal th...
Next Document:  Listeria monocytogenes infection in the face of innate immunity.